Diabetes - Nursing Case Study

Pathophysiology

• Primary mechanism: Insulin resistance occurs, where cells in muscles, fat, and liver do not respond effectively to insulin, leading to impaired glucose uptake and increased blood glucose levels.

• Secondary mechanism: Beta-cell dysfunction in the pancreas results in inadequate insulin secretion, further exacerbating hyperglycemia as the body cannot compensate for insulin resistance.

• Key complication: Chronic high blood glucose damages blood vessels, increasing the risk of cardiovascular diseases, neuropathy, nephropathy, and retinopathy, highlighting the importance of early detection and management.

Patient Profile

Demographics:

52-year-old female, office manager

History:

• Key past medical history: Diagnosed with type 2 diabetes 8 years ago, hypertension, hyperlipidemia

• Current medications: Metformin 1000 mg twice daily, Lisinopril 20 mg once daily, Atorvastatin 40 mg once daily, Aspirin 81 mg once daily

• Allergies: Penicillin

Current Presentation:

• Chief complaint: Increasing fatigue and intermittent blurred vision

• Key symptoms: Numbness and tingling in feet, frequent urination, unexplained weight loss over the past 3 months

• Vital signs: Blood pressure 145/92 mmHg, heart rate 88 bpm, respiratory rate 18 breaths per minute, temperature 98.6°F, blood glucose level 210 mg/dL

Section 1

During the initial assessment, the patient, Mrs. Thompson, presents with signs indicative of potential diabetic complications. Her blood pressure remains elevated at 145/92 mmHg, and her blood glucose level of 210 mg/dL suggests poor glycemic control. The numbness and tingling in her feet, in conjunction with her blurred vision, raise concerns for diabetic neuropathy and retinopathy. These symptoms, coupled with her unexplained weight loss and fatigue, suggest that her diabetes may not be adequately managed, potentially leading to further complications.

A comprehensive foot exam reveals diminished sensation to monofilament testing, particularly in the distal extremities, suggesting peripheral neuropathy. An ophthalmologic evaluation is recommended due to the blurred vision, considering the risk of diabetic retinopathy. Laboratory tests, including a Hemoglobin A1c, reveal a level of 9.2%, indicating chronic hyperglycemia over the past three months. Additionally, a urine microalbumin test shows elevated levels, suggesting early nephropathy.

The clinical team discusses the importance of improving Mrs. Thompson's glycemic control and blood pressure management to prevent further complications. They consider adjusting her medication regimen, including potential insulin therapy to better manage her blood glucose levels, and emphasize lifestyle modifications such as diet and exercise. Mrs. Thompson is advised to monitor her blood glucose levels more frequently and to follow up with a diabetes educator for further support. The team plans to reassess her response to these interventions and schedule follow-up appointments to monitor her progress and adjust her treatment plan as necessary.

Section 2

Two weeks after the initial intervention adjustments, Mrs. Thompson returns for a follow-up appointment. The clinical team notes some positive changes in her condition; however, there are also new areas of concern. Her blood pressure has improved slightly, now reading 138/88 mmHg, indicating a modest response to the recent antihypertensive adjustments. Her fasting blood glucose levels have also shown some stabilization, averaging around 180 mg/dL. However, despite these improvements, Mrs. Thompson reports persistent fatigue and has developed new symptoms, including swelling in her lower extremities and increased nocturia.

New laboratory tests reveal a slight increase in her creatinine levels, now at 1.3 mg/dL, with an estimated glomerular filtration rate (eGFR) of 55 mL/min/1.73 m², suggesting a progression of her diabetic nephropathy. Additionally, a repeat urine microalbumin test shows further elevation, reinforcing concerns about her kidney function. Her Hemoglobin A1c remains high at 8.8%, indicating that while there has been some improvement, her glycemic control is still suboptimal.

The clinical team discusses the need for a more aggressive approach to manage her diabetes and its complications. They consider intensifying her pharmacotherapy, potentially adding an SGLT2 inhibitor to address both hyperglycemia and renal protection. Emphasis is placed on the importance of Mrs. Thompson adhering to her prescribed medication regimen and lifestyle modifications. Regular follow-up appointments are scheduled to closely monitor her renal function and adjust her treatment plan as needed. The team also arranges for a nephrology consultation to provide specialized care for her worsening nephropathy, highlighting the interconnectedness of her diabetic complications and the need for a comprehensive management strategy.

Section 3

Three weeks after intensifying her treatment regimen, Mrs. Thompson returns for another follow-up appointment. The clinical team immediately notices some changes in her condition. Her blood pressure has further improved to 132/84 mmHg, suggesting that the adjustments in her antihypertensive therapy are taking effect. Her fasting blood glucose levels have decreased slightly, now averaging around 165 mg/dL, indicating a slow but positive response to the addition of the SGLT2 inhibitor. However, Mrs. Thompson expresses concern about persistent fatigue and has started experiencing mild dizziness, particularly when standing up quickly.

A new set of laboratory tests reveals some noteworthy results. Her creatinine levels have stabilized at 1.3 mg/dL, and her eGFR has improved slightly to 58 mL/min/1.73 m², which is an encouraging sign for her renal function. However, her urine microalbumin levels remain elevated, underscoring the ongoing risk to her kidneys. Additionally, her Hemoglobin A1c has decreased to 8.4%, reflecting gradual improvements in glycemic control, though it remains above target. Given the recent onset of dizziness, the clinical team checks her electrolyte levels and notes a mild hyponatremia with a sodium level of 133 mmol/L.

These findings prompt the team to consider the possibility of orthostatic hypotension as a side effect of the intensified antihypertensive therapy and the SGLT2 inhibitor, along with the need to address her electrolyte imbalance. They decide to adjust her medication dosage to mitigate these effects while maintaining her blood pressure and glucose control. Education is provided to Mrs. Thompson on recognizing symptoms of orthostatic hypotension and strategies to manage them, such as rising slowly from sitting or lying positions. The team emphasizes the importance of staying hydrated and schedules another follow-up to reassess her symptoms and lab values, ensuring her treatment remains balanced and effective.

Section 4

Two weeks after the medication adjustments, Mrs. Thompson returns to the clinic for a follow-up appointment. During the initial assessment, the clinical team observes that her blood pressure has stabilized at 128/82 mmHg, suggesting continued effectiveness of her antihypertensive regimen. However, Mrs. Thompson reports ongoing episodes of dizziness upon standing and increased fatigue, which have begun to interfere with her daily activities. She also notes a new symptom of intermittent palpitations that occur mostly in the evenings.

The team conducts a thorough physical examination and orders another set of laboratory tests. Her heart rate is slightly elevated at 92 beats per minute, and her respiratory rate is 18 breaths per minute. Her sodium levels remain mildly low at 132 mmol/L, and new laboratory results reveal a further decrease in her potassium levels to 3.2 mmol/L, indicating hypokalemia. An ECG shows occasional premature ventricular contractions, which could be linked to her electrolyte imbalance. Given these findings, the clinical team suspects that the combination of her medications, particularly the SGLT2 inhibitor, may be contributing to her electrolyte disturbances and subsequent symptoms.

In response, the team decides to adjust her medication regimen again, reducing the dosage of the SGLT2 inhibitor and supplementing her diet with potassium-rich foods. They provide her with education on dietary modifications and emphasize the importance of regular monitoring of her symptoms and electrolyte levels. The team also arranges for a cardiology consultation to further evaluate her palpitations and possible cardiac involvement. Mrs. Thompson is scheduled for another follow-up in two weeks to reassess her condition, with a focus on ensuring her treatment plan is both effective and safe.

Section 5

Two weeks later, Mrs. Thompson returns for her follow-up appointment. The clinical team observes that her blood pressure remains stable at 126/80 mmHg, and her heart rate has decreased slightly to 88 beats per minute. However, Mrs. Thompson continues to report intermittent episodes of dizziness and fatigue, albeit with some reduction in intensity. She also notes that the palpitations have become less frequent, although they still occur sporadically. Encouraged by these modest improvements, the team investigates further to ensure her symptoms are effectively managed and to prevent any potential complications.

The latest laboratory results reveal that her potassium levels have improved slightly to 3.5 mmol/L, which is still on the lower side but within the normal range. Her sodium levels have normalized at 135 mmol/L. Despite these positive changes, the ECG still shows occasional premature ventricular contractions, suggesting that while the electrolyte imbalance is correcting, there may be underlying cardiac issues that need to be addressed. The team acknowledges the importance of ongoing monitoring and decides to continue her current medication regimen while increasing the frequency of her potassium intake through both diet and supplements.

In light of the persistent ECG findings and symptoms, the cardiology consultation proves timely. The cardiologist identifies that Mrs. Thompson's palpitations and premature ventricular contractions are likely exacerbated by a combination of her previous electrolyte disturbances and possible autonomic dysfunction related to her diabetes. They recommend a Holter monitor to track her cardiac rhythm over a 24-hour period, providing a clearer picture of her heart's activity and enabling a more targeted intervention plan. This approach aims to ensure Mrs. Thompson's heart health is closely monitored and any necessary treatments are promptly initiated, helping to mitigate the risk of further cardiac complications. The clinical team emphasizes the importance of adherence to follow-up appointments and encourages Mrs. Thompson to maintain her dietary adjustments and medication regimen to support her overall well-being.